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Befo re the 1940s, viral hepatitis was defined chiefly on 
the basis of its epidemiologic characteristics. Two types 
were recognized: infectious hepatitis, associated wi th a 
short incubation period and a fecal-oral mechanism of 
transmission; and serum hepatitis, associated wi th a 
long incubation period and a parenteral mechanism 
of transmission. Studies in human volunteers were 
init iated because of fai lure to transmit hepatitis to 
laboratory animals (1-4). These studies conf irmed the 
existence of two immunological ly dist inct hepatitis 
agents, which are now designated as hepatitis A virus 
and hepatitis B virus. The development and use of 
sensitive tests to detect these two viruses revealed an-
other type of hepatitis caused by previously unrec-
ognized agents (5-9). This type of viral hepatitis has 
been designated as non-A, non-B hepatitis, which is a 
diagnosis of exclusion because sensitive and specific 
immunologic tests are not yet available. 
Technologic advances in recent years have given us not 
only the ability to accurately diagnose and characterize 
the different types of hepatitis, but they have also pro-
vided us wi th the means for prevent ion. Improved 
understanding of the epidemiology of the different 
types of hepatitis in combination wi th the means for 
effective intervention ( immune globul ins, hepatitis B 
vaccine) has resulted in the current recommendations 
for preexposure and postexposure prophylaxis against 
viral hepatitis. This paper wi l l discuss the current strat-
egies to prevent viral hepatitis types A, B, and non-A, 
non-B. 
Hepatitis A 
Hepatitis A is caused by a 27-nm RNA virus (10) that is a 
member of the picornavirus family. It has an incubation 
period ranging f rom 15 to 50 days (mean: 30 days) and 
usually causes a mild or subclinical disease in children 
but a more severe illness in adults (11). The overall 
case-fatality rate is low, about 0 .1% among hospitalized 
patients. Infection wi th hepatitis A virus induces immu-
nity to reinfection. The infection is not associated wi th 
development of chronic liver disease, and no virus 
carrier state has been identif ied (4,12,13). Hepatitis A is 
transmitted by the fecal-oral route, principally by direct 
contact. Persons at highest risk of acquiring the disease 
are household and sexual contacts of a patient wi th 
hepatitis A. Levels of hepatitis A virus particles detect-
able in stool are usually at their highest at or before the 
t ime serum aminotransferase levels become elevated, 
and they drop significantly before the onset of jaundice 
(14-16). Maximal excretion of virus occurs during the 
late incubation period of hepatitis A, and epidemiologic 
studies have shown that this period of maximal shed-
ding of virus correlates well wi th periods of maximal 
disease transmission (17). 
As early as the 1940s, immune globul in (IG) was shown 
to be protective against hepatitis A (18). Its prophylactic 
value is greatest when given before exposure or early in 
the incubation per iod. Giving IG more than two weeks 
after exposure is not indicated. The Immunization Prac-
tices Advisory Committee recommends IG prophylaxis 
for hepatitis A (19) for all household and sexual contacts 
of persons wi th hepatitis A, and for the control of 
outbreaks wi th in day care centers (20) and institutions 
for custodial care, such as prisons and facilities for the 
developmentally disabled. Routine administration of IG 
is not indicated for those who have had contact wi th a 
patient wi th hepatitis A at offices, factories, or schools. 
Routine IG prophylaxis is not indicated for hospital 
personnel. Outbreaks of hepatitis A wi th in hospitals 
have largely been the result of transmission f rom 
patients who were fecally incontinent and hospitalized 
during the incubation period of hepatitis A infection 
with a diagnosis unrelated to hepatitis (21-25). Since 
hepatitis A infection was not suspected in these situ-
ations, the opportuni ty to use IG never arose. By the 
time a patient presents wi th symptoms and is admitted 
to the hospital, the amount of hepatitis A virus in stool 
has decreased to the point that the probabil ity of trans-
mission to personnel or other patients is remote, and IG 
prophylaxis is not necessary (26). The prevention of 
hepatitis A in hospitals should emphasize good aseptic 
techniques in the care of all patients, not only those 
suspected of having an infectious disease. If an out-
break of hepatitis A does occur, however, and the 
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individuals exposed can be identif ied wi th in two weeks 
of their exposure, IG prophylaxis should be considered 
to prevent secondary transmission. 
If a food handler is diagnosed as having hepatitis A, 
common source transmission is possible. IG should be 
administered to other kitchen employees but is rarely 
indicated for patrons. However, prophylaxis of patrons 
is sometimes considered if: 1) the infected person is 
d i rect ly invo lved in hand l ing uncooked foods or 
cooked foods before they are eaten; 2) the hygienic 
practices of the food handler are deficient; 3) consumers 
have had multiple exposures to the food handler (as in 
institutions); and 4) consumers can be identified and 
treated within two weeks of exposure (27). 
Preexposure prophylaxis against hepatitis A is recom-
mended for persons travel ing to foreign countr ies 
under certain condit ions. IG is not recommended for 
travelers who fo l low the usual tourist routes since they 
may be at no greater risk of getting hepatitis A than they 
would be in the United States. Travelers to high-risk 
areas outside ordinary tourist routes may be at in-
creased risk. For such travelers, who are at risk for up to 
two to three months, a single IG dose of 0.02 ml/kg is 
recommended. For more prolonged travel, 0.06 ml/kg 
should be given every five months. As wi th any enteric 
infection, the best way to prevent hepatitis A is to avoid 
potentially contaminated water and food. 
Hepatitis B 
Hepatitis B is caused by a 42-nm, double-shelled DNA 
virus (28-29) of the hepadna virus class. Its incubation 
period ranges from 50 to 180 days (mean: 60 to 90 days). 
Although certain clinical characteristics of hepatitis B 
may differ f rom those of hepatitis A, considerable over-
lap occurs, making it impossible to distinguish between 
the two types by clinical criteria alone. The overall 
case-fatality rate is higher than that for hepatitis A but 
generally does not exceed 1 % among hospital ized 
patients. In adults, approximately 6% to 10% of acute 
infections may result in chronic carriage of hepatitis B 
surface antigen (HBsAg) (13). The carrier state can be 
completely asymptomatic or associated wi th active liver 
disease. Cirrhosis and pr imary hepatocel lu lar car-
cinoma are potential consequences of chronic hepatitis 
B virus infection (30). 
Carriers and persons wi th acute infect ion have the 
highest concentrations of hepatitis B virus in blood and 
serous f lu id ; less is present in other body f lu ids, such as 
saliva and semen, and transmission involving these 
sources may be much less efficient (31-35). Hepatitis B is 
transmitted by percutaneous or permucosal exposure 
to infective blood or body f luids, such as might occur 
th rough punctures w i t h contaminated needles or 
through sexual contact. 
Before 1982, immune globul in preparations available 
for protection against hepatitis B were routinely recom-
mended only for postexposure prophylaxis (19). Wi th 
the introduct ion of the hepatitis B vaccine, however, a 
safe and effective means of preexposure prophylaxis is 
now available (36,37). 
The Immunization Practices Advisory Commit tee rec-
ommends preexposure vaccinat ion for persons at 
substantial risk of hepatitis B virus infection who are 
demonstrated or judged likely to be susceptible (38). 
Such persons include health care workers (hospital and 
nonhospital based) who have frequent contact wi th 
blood and blood products, clients and staff of insti-
t u t i o n s fo r the men ta l l y r e t a r d e d , hemod ia l ys i s 
patients, homosexually active men, users of il l icit in-
jectable drugs, patients wi th clott ing disorders who 
receive factor V l l l or IX concentrates, household and 
sexual contacts of hepatitis B virus carriers, special 
high-risk populations such as Alaskan natives and im-
migrants and refugees f rom areas of highly endemic 
d isease, and inmates of l o n g - t e r m c o r r e c t i o n a l 
facilities. 
Primary adul t vaccinat ion consists of three intra-
muscular doses of 1.0 ml of vaccine (20 |i.g/1.0 ml) each. 
The second and third doses should be given one and six 
months, respectively, after the first. For patients under-
going hemodialysis and for other immunosuppressed 
patients, three 2-ml doses (40 jjtg) should be used. For 
children under ten years of age, three similarly spaced 
doses of 0.5 ml (10 p.g) are sufficient. Since hepatitis B 
vaccine is an inactivated product, it is presumed that 
there wil l be no interference wi th other simultaneously 
administered vaccines. In addi t ion, passively acquired 
antibodies, such as those f rom hepatitis B immune 
globulin (HBIG) administration, wi l l not interfere with 
active immunization (39). 
Postexposure prophylaxis against hepatitis B should be 
considered for infants born to HBsAg-positive mothers, 
for individuals who sustain accidental percutaneous or 
permucosal exposure to HBsAg-positive b lood, and for 
susceptible individuals who have sexual exposure to an 
HBsAg-posit ive person. Previous recommendat ions 
have relied almost solely on passive immunizat ion wi th 
immune globul in preparations (19,38). Recently, how-
ever, a combinat ion of hepatitis B vaccine wi th HBIG has 
been shown to be highly efficacious in preventing hep-
atitis B infection for perinatal exposures (40). This in-
formation has resulted in revised recommendations by 
the Immunizat ion Practices Advisory Committee for 
postexposure prophylaxis (41). A summary fol lows, but 
consult recommendations for complete details, par-
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ticularly wi th respect to screening for high-risk and 
susceptible individuals. 
For infants born to HBsAg-positive mothers, HBIG (0.5 
ml) should be administered as soon after birth as pos-
sible, preferably wi th in 12 hours. Hepatitis B vaccine 
should be administered intramuscularly in three doses 
of 0.5 ml (10 p.g) of vaccine each. Thefirst dose should be 
given wi th in seven days of birth and may be given 
concurrently wi th HBIG but at a separate site. The sec-
ond and third doses should be given one month and six 
months, respectively, after the first (Table I). No further 
doses of HBIG need to be administered. 
For accidental percutaneous or permucosal exposure to 
blood that might contain HBsAg, the decision to admin-
ister an immune globul in (IG or HBIG) must consider 
several factors: 1) whether the source of b lood is known 
or unknown, 2) whether the HBsAg status of the source 
is known or unknown , and 3) for maximum effec-
tiveness, globul in should be given as soon after ex-
posure as possible, preferably wi th in 24 hours and no 
TABLE I 
Schedule of Postexposure Prophylaxis against Hepatitis B 
for Infants Born to HBsAg-Positive Mothers 
Age HBIG Vaccine 
Wi th in 12 hours 0,5 ml IM 0.5 ml (lOug) IM — W i t h i n 7days* 
1 month 0,5 m| ( io |j,g) |M 
6 months 0.5 ml (10 p,g) IM 
* The first dose can be given at same t ime as HBIG but at a separate 
site. 
later than seven days after exposure. The fol lowing 
recommendations are based on these factors and are 
summarized in Table 11. 
1. Source known , HBsAg status posit ive. One 
dose of HBIG (0.06 ml/kg) should be given as 
soon as possible after exposure, preferably 
TABLE II 
Postexposure Prophylaxis of Acute Exposure to Hepatitis B Virus 
Exposure 
PERCUTANEOUS 
HBsAg positive 
HBsAg status unknown . 
Source known : 
High Risk 
Testing 
Low Risk 
SEXUAL 
HBsAg—if results 
can be known 
w i th in 7 days 
of exposure 
No 
HBsAg status unknown . 
Source unknown No 
Ant i -HBc** 
or 
Anti-HBs 
Globul in 
HBIG (0,06 ml/kg) 
w i th in 24 hours 
IG (0,06 ml/kg) 
immediately, if 
TEST POSITIVE 
HBIG (0,06 ml/kg) 
If TEST NEGATIVE 
noth ing 
Noth ing or 
IG (0,06 ml/kg) 
Noth ing or 
IG (0,06 ml/kg) 
HBIG (0.06 ml/kg) 
w i th in 14 days 
of sexual contact 
Vaccine 
1.0 ml w i th in 7 days*; 
repeat at 1 and 6 mo . 
1.0 m l * ; repeat 
at 1 and 6 mo. 
* The first dose can be given at same t ime as HBIG but at a separate site; for persons <10years of age, useO,5 ml 
" A n t i - H B c = ant ibody to hepatit is B core antigen 
Anti-HBs = ant ibody to hepatitis B surface antigen 
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wi th in 24 hours. Hepatitis B vaccine, 1.0 ml (20 
p-g), should be given intramuscularly at a sep-
arate site as soon as possible, but wi th in seven 
days of exposure, wi th the second and third 
doses given one month and six months, respec-
tively, after the first. If HBIG is unavailable, IG 
may be given in an equivalent dosage. If an 
individual has received at least two doses of 
hepatitis B vaccine before an accidental ex-
posure, no treatment is necessary if serologic 
tests show adequate levels (>10 SRU by radio-
immunoassay) of ant ibodyto HBsAg (anti-HBs). 
For persons who choose not to receive the 
hepatit is B vaccine, the first dose of HBIG 
should be fo l lowed by a second identical dose 
one month later. 
2. Source known, HBsAg status unknown. If the 
source is someone at high risk of being HBsAg-
positive (patients wi th acute, unconf irmed viral 
hepatitis; retarded individuals with a history of 
insti tut ionalization; patients receiving hemo-
dialysis; persons of Asian or ig in ; homosexual 
men ; or il l icit intravenous drug users), and 
HBsAg test results can be known wi th in seven 
days of the exposure, IG (0.06 ml/kg) should be 
given immediately, preferably wi th in 24 hours, 
and an HBsAg test on the source patient ob-
tained. If test results are positive, HBIG (0.06 
ml/kg) should be given along wi th the first dose 
of hepatitis B vaccine. The second and third 
doses of hepatitis B vaccine should be given 
one month and six months, respectively, after 
the first. If HBsAg test results cannot be known 
wi th in seven days of the exposure, the decision 
to use IG or HBIG (with or wi thout hepatitis B 
vaccine) must be based on the clinical and 
epidemiologic characteristics of exposure and 
the availability of g lobul in , wi th the physician 
remembering the importance of characterizing 
the source and giving globul in as soon after 
exposure as possible. If the source is at low risk 
of being HBsAg-positive (such as the average 
hospital patient), prophylaxis is opt ional , and 
HBsAg test ing of the source is not recom-
mended. If an immune globul in is to be used, 
IG (0.06 ml/kg) should be given promptly, pref-
erably wi th in 24 hours. No further action is 
necessary. 
3. Source u n k n o w n , HBsAg status u n k n o w n . 
Prophylaxis is opt ional. If an immune globul in 
is to be used, IC (0.06 ml/kg) should be given 
promptly, preferably wi th in 24 hours. No fur-
ther action is necessary. 
For heterosexual contacts of persons with acute hepati-
tis B virus infect ion, hepatitis B vaccine is not routinely 
recommended, since approximately 90% of persons 
with acute hepatitis B become HBsAg-negative wi th in 15 
weeks of diagnosis and, therefore, are no longer at risk 
for transmitt ing infection to their sexual partner(s). A 
single dose of HBIG (0.06 ml/kg) is recommended for 
susceptible individuals who have had sexual contact 
wi th an HBsAg-positive person if HBIG can be given 
within 14 days of the last sexual contact, and for persons 
who wi l l continue to have sexual contact wi th an indi-
vidual wi th acute hepatitis B whi le that individual re-
mains HBsAg-positive (Table II). For heterosexuals, a 
second dose of HBIG should be given if the index 
patient remains HBsAg-positive three months after de-
tect ion. If the index patient is a known HBsAg carrier or 
remains HBsAg-positive for six months, hepatitis B vac-
cine should be offered to regular sexual contacts. For 
homosexual men, the hepatitis B vaccine series should 
be initiated at the t ime HBIG is given, since hepatitis B 
vaccine is recommended for all susceptible homosexual 
men. Addit ional doses of HBIG are unnecessary if vac-
cine is given. Because current lots of IG contain anti-
HBs, IG remains an important alternative to HBIG when 
HBIG is unavailable. 
Hepatitis Non-A, Non-B 
There is both epidemiologic and experimental evidence 
to suggest that more than one etiologic agent is respon-
sible for non-A, non-B hepatitis (42-48). None of these 
agents have been identif ied as yet, nor has any specific 
test been developed to accurately diagnose this dis-
ease. The incubation period of non-A, non-B hepatitis 
spans those of hepatitis A and hepatitis B, ranging f rom 
2 to 22 weeks (mean: 7 to 9). Strain-specific immuni ty to 
non-A, non-B hepatitis has been conf i rmed by cross-
challenge experiments in animals (49). The existence of 
a carrier state has been identif ied (50-53), and chronic 
liver disease is a frequent sequela after acute infection 
(54-59). Common-source outbreaks and sporadic cases 
of non-A, non-B hepatitis apparentiy due to a fecal-oral 
agent have been observed in other countries (60-62). In 
this country, non-A, non-B hepatitis was initially iden-
tif ied as a transfusion-associated disease; however, a 
substantial proport ion of this type of hepatitis occurs in 
the communi ty independent of b lood transfusions. 
Community-acquired non-A, non-B hepatitis has been 
associated with other percutaneous exposure, such as 
intravenous drug use and employment in health-related 
occupations involving frequent contact wi th b lood (52). 
Person-to-person transmission has also been ident i f ied, 
but the mechanism by which such transmission takes 
place is unknown (52). 
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Although several studies have attempted to assess the 
value of prophylaxis wi th immune globulins against 
non-A, non-B hepatitis, the results have been equivocal 
(63,64), and no specific recommendations can be made. 
However, for persons wi th percutaneous exposure to 
blood f rom a patient wi th non-A, non-B hepatitis, it 
wou ld appear reasonable to administer IG (0.06 ml/kg) 
as soon after exposure as possible. 
We now have the means to prevent or modi fy infection 
wi th hepatitis A virus and hepatitis B virus under certain 
c i rcumstances . A p p r o p r i a t e p rophy lax is requ i res 
1) recognition o fwh ich individuals are at risk foracquir-
ing each type of viral hepatitis by virtue of their charac-
teristics, such as direct exposure, occupat ion, lifestyle, 
or ethnicity, 2) accurate serologic diagnosis of the type 
of hepatitis in the index case, and 3) knowledge of 
currently recommended prophylactic regimens. Only 
when all these factors are considered can appropriate 
intervention effectively be used. 
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